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S U M M A R Y
Objective: Negative conversion of sputum culture is a useful marker for predicting treatment outcome
and relapse of pulmonary tuberculosis (TB). The effect of drug resistance on negative conversion of
sputum culture with treatment was evaluated in this study.
Methods: A total of 535 patients with culture-proven pulmonary TB were classiﬁed into three groups:
drug-susceptible (DS), other drug-resistant (ODR), and multidrug-resistant/extensively drug-resistant
(MDR/XDR). Rates of conversion of sputum culture at 4, 8, and 12 weeks were compared.
Results: At 4 weeks of treatment, the conversion rate in the DS group (52.7%) was higher than that in the
ODR group (30.8%, p = 0.003), but was not different compared with the MDR group (45.7%, p = 0.427). At
8 weeks, the conversion rate in the DS group (76.3%) was higher than that in the ODR (63.5%, p = 0.042)
and MDR groups (60.0%, p = 0.031). At 12 weeks, the conversion rate in the DS group (85.9%) tended to be
higher than that in the MDR group (74.3%, p = 0.062), but was not different from that in the ODR group
(84.6%, p = 0.796).
Conclusion: The pattern of resistance to anti-TB drugs affects culture conversion rates in the early phase
of treatment and also prolongs the time to culture conversion.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Despite the reduction in incidence and prevalence of tubercu-
losis (TB) through efforts worldwide, TB remains a global health
problem. In 2013, 9.0 million new cases of TB, 1.5 million deaths
among HIV-negative people with TB, and 360 000 deaths among
HIV-positive people with TB were reported.1
To monitor the outcomes of treatment, sputum should be
obtained for microscopic examination and culture at monthly
intervals until two consecutive culture specimens are negative and
also at the completion of treatment.2 The sputum culture-negative
conversion rate after 2 months of anti-TB treatment is a reliable* Corresponding author. Tel.: +82 2 2072 2059; fax: +82 2 762 9662.
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).surrogate marker for relapse after the completion of treatment.3 In
addition, a delay in conversion is associated with the risk of
acquiring drug resistance.4 Among patients with multidrug-
resistant (MDR) TB, those who have early conversion to negative
results show better treatment outcomes than patients with
delayed culture conversion.5
Resistance to anti-TB drugs, including mono-resistance, multi-
drug resistance, and extensive drug resistance, causes worse
treatment outcomes.6,7 However, the difference in rate of
conversion at certain time points or the time to conversion in
TB patients with varying resistance to anti-TB drugs remains
unclear. Previous studies on this issue have had limitations, such as
a small number of patients or the absence of a certain drug
resistance group.8–10 Therefore, the aim of this study was to
determine the effect of the drug resistance pattern on the monthly
conversion rate of sputum culture, as well as the time to culture
conversion.ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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2.1. Patients
This retrospective cohort study included all consecutive
patients who were diagnosed with culture-proven pulmonary
TB and treated with the standard World Health Organization
(WHO) regimen between January 1, 2009 and December 31,
2012. The patients were from Seoul National University Hospital, a
tertiary referral hospital in South Korea. Patients for whom drug
susceptibility test results were not available and patients who
were missing the results of mycobacterial culture of sputum at
8 weeks after the initiation of anti-TB treatment were excluded.
The study was approved by the ethics committee of the Seoul
National University Hospital Institutional Review Board.
2.2. Data collection
Patient demographic data, as well as past medical history and
co-morbidities, were reviewed and recorded. The results of acid-
fast staining and mycobacterial culture of sputum before and
during treatment, drug susceptibility test results, and details of the
treatment regimen were also collected.
2.3. Laboratory processing of specimens
For all specimens, an acid-fast bacillus (AFB) smear was
performed using auramine–rhodamine staining and conﬁrmed
by Ziehl–Neelsen staining. Culture was performed in Ogawa
medium for 8 weeks in 5–10% CO2 incubators and in BACTEC MGIT
for 6 weeks. When cultured, the isolation of Mycobacterium
tuberculosis was conﬁrmed using the Seeplex MTB/NTM ACE
detection method (Seegene, Seoul, South Korea).
The mycobacteriology laboratory of the study institution is a
biosafety level 3 facility (BSL-3; with inward directional airﬂow
and double-door entry). Two biosafety cabinets are used (both
class II, type A2), and the processing and handling of mycobacterial
colonies is limited to one cabinet. For pipetting, ﬁlter tips are
always applied and two or more tube caps are not allowed to be
opened at one time. After work is completed for the day, ultraviolet
irradiation is applied to the inside of the biological safety cabinet
and the entire mycobacteriology laboratory until the next
morning.
Although mycobacterial cultures were performed at Seoul
National University Hospital, drug susceptibility testing was
performed at the Korean Institute of Tuberculosis (Osong, South
Korea), which is the supranational reference laboratory for TB.
Resistance to each drug that was tested was deﬁned as 1%
bacterial growth in Lo¨wenstein–Jensen medium. The absolute
concentration method was used, with the following critical
concentrations of anti-TB drugs: isoniazid 0.2 mg/ml, streptomycin
10.0 mg/ml, ethambutol 2.0 mg/ml, rifampicin 40.0 mg/ml, para-
aminosalicylic acid 1.0 mg/ml, prothionamide 40.0 mg/ml, cyclo-
serine 30.0 mg/ml, kanamycin 40.0 mg/ml, capreomycin 40.0 mg/
ml, oﬂoxacin 2.0 mg/ml, levoﬂoxacin 2.0 mg/ml, and moxiﬂoxacin
2.0 mg/ml. Pyrazinamide susceptibility was determined using the
pyrazinamidase test.11
2.4. Deﬁnitions and comparisons
Patients were classiﬁed into three groups according to the
pattern of drug resistance: susceptible to all ﬁrst-line anti-TB drugs
(drug-susceptible (DS) group), presence of mono- or poly-
resistance to ﬁrst-line drugs but not meeting the deﬁnition for
MDR-TB (other drug-resistant (ODR) group), and MDR-TB,
including extensively drug-resistant (XDR) TB (MDR/XDR group).Deﬁnitions of MDR-TB and XDR-TB were those given in the WHO
guidelines.2 Negative culture conversion was deﬁned as two
consecutive negative sputum cultures in liquid medium. The date
of conversion was deﬁned as the date of ﬁrst negative culture
satisfying culture conversion. Negative sputum culture followed
by contaminated culture was also regarded as culture conversion if
a subsequent culture gave a negative result. If patients could not
expectorate sputum after one occurrence of negative sputum
culture, this was also deﬁned as culture conversion.
The rate of conversion at 4, 8, and 12 weeks of anti-TB treatment
and the time to conversion of sputum were compared among the
three groups. A 1-week period was allowed for each time point if
results of mycobacterial culture of sputum were unavailable at the
predeﬁned time points of 4, 8, and 12 weeks. The time to
conversion was deﬁned as the number of days from initiation of
anti-TB treatment to the date of conversion. In the MDR/XDR
group, the time to conversion was counted from the date of
initiation of second-line anti-TB drugs.
Treatment outcomes were classiﬁed based on guidelines
published by the WHO for drug-susceptible TB, as well as drug-
resistant TB.12 Being ‘transferred’ or ‘still on treatment’ was
determined at the time of writing the manuscript.
2.5. Statistical analysis
Baseline demographic and clinical characteristics are summa-
rized using descriptive statistics, such as the median and
interquartile range (IQR). For comparisons between groups, p-
values obtained using Pearson’s Chi-square test, one-way analysis
of variance, or the Wilcoxon–Mann–Whitney rank sum test, as
appropriate, are reported. The Kaplan–Meier method and log-rank
test were used to compare the time to conversion. A p-value of
<0.05 was considered statistically signiﬁcant. All analyses were
conducted using Stata Statistics version 13 (StataCorp, College
Station, TX, USA).
3. Results
3.1. Baseline characteristics of the patients
A total of 535 patients were included in the study and analyzed.
Of these, 448 (83.7%) patients were allocated to the DS group, 52
(9.7%) to the ODR group, and 35 (6.5%; 28 MDR patients and seven
XDR patients) to the MDR/XDR group. Patients in the MDR/XDR
group were younger (median 41 years) than those in the other
groups (p = 0.002). Patients in the MDR/XDR group were more
likely to have a history of previous TB treatment (55.9%, p < 0.001)
and a positive AFB sputum smear at the time of diagnosis (48.6%,
p = 0.008). Baseline characteristics of the patients are shown in
Table 1.
Patients in the DS group were more likely to achieve cure, while
those in the MDR/XDR group were more likely to be transferred or
were still on treatment. In the DS group, 404 (90.2%) patients were
classiﬁed as cured or completed treatment. In the MDR/XDR group,
27 (77.1%) patients were classiﬁed as having successful treatment
(Table 2). The number of patients still on treatment was two in the
DS group, one in the ODR group, and two in the MDR/XDR group.
3.2. Comparison of culture conversion rates at 4, 8, and 12 weeks of
treatment
At the end of the ﬁrst 4 weeks of treatment, the rate of
conversion in the DS group (52.7%) was higher than that in the ODR
group (30.8%, p = 0.003), but was not different from that in the
MDR/XDR group (45.7%, p = 0.427). At 8 weeks, the proportion of
patients with negative conversion in the DS group increased to
Table 1
Demographic and baseline characteristics of the three groups of patients
All drug-sensitive Other drug-resistant MDR or XDR p-Value
Number (total = 535) 448 52 35
Age, years, median (IQR) 56 (39, 70) 55 (37, 69) 41 (33, 55) 0.002
Male, n (%) 264 (58.9) 30 (57.7) 24 (68.6) 0.52
Body weight, kg, median (IQR) 55 (49, 64.2) 56.3 (50, 62.2) 56.8 (49, 67) 0.28
Sputum studies
Positive acid-fast staining, n (%) 140 (31.3) 19 (36.5) 17 (48.6) 0.008
Time to culture of M. tuberculosis, days, median (IQR) 16 (12, 20) 14 (10.5, 19) 15 (11, 20) 0.39
History of tuberculosis, n (%) 67 (15.2) 11 (22.0) 19 (55.9) <0.001
Comorbidities
Diabetes, n (%) 81 (18.1) 11 (21.2) 3 (8.6) 0.29
Malignancy, n (%) 54 (12.1) 7 (13.5) 1 (2.9) 0.24
Immunosuppressants, n (%) 22 (4.9) 1 (1.9) 2 (2.9) 0.55
HIV/AIDS, n (%) 1 (0.2) 1 (1.9) 2 (5.7) 0.001
Chronic liver disease, n (%) 34 (7.6) 4 (7.7) 1 (2.9) 0.58
Chronic kidney disease, n (%) 21 (4.7) 2 (3.9) 1 (2.9) 0.86
Smoking status
Current smoker, n (%) 81 (18.1) 6 (11.5) 8 (8.4) 0.82
Pack-years, median (IQR) 30 (15, 50) 40 (30, 40) 20 (15, 40) 0.36
Radiographic characteristics
Presence of a cavity, n (%) 100 (26.1) 10 (25.6) 11 (34.4) 0.59
Bilateral involvement, n (%) 194 (50.7) 27 (69.2) 19 (59.4) 0.001
MDR, multidrug-resistant; XDR, extensively drug-resistant; IQR, interquartile range.
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to 63.5% (p = 0.042), and that in the MDR/XDR group, which had
increased to 60.0% (p = 0.031). At 12 weeks, the conversion rate
was still higher in the DS group (85.9%) than in the MDR/XDR group
(74.3%, p = 0.062), but was not different compared with the ODR
group (84.6%, p = 0.796, Table 3).
Conversion rates were also analyzed using a stricter deﬁnition
of negative culture conversion, as follows: two consecutive
negative cultures were taken at least 30 days apart, and patients
who could not expectorate sputum after one occurrence of
negative sputum culture were excluded. Although conversion
rates at 4, 8, and 12 weeks were lower than those in the previous
analysis, the overall differences and statistical signiﬁcance wereTable 2
Outcomes of treatment in the three groups
All
drug-sensitive
Other
drug-resistant
MDR or
XDR
p-Value
Number (total = 535) 448 52 35
Results, n (%)
Cured or treatment
completed
404 (90.2) 45 (86.5) 27 (77.1)
Failed 8 (1.8) 1 (1.9) 2 (5.7)
Died 5 (1.1) 1 (1.9) 0 (0.0)
Lost to follow-up 31 (6.9) 5 (9.7) 6 (17.1)
Not evaluated 14 (3.1) 2 (3.9) 4 (11.4)
Time to negative culture conversion
Mean  SD 53.1  68.1 59.3  36.9 109.2  175.1 <0.001
Median (IQR) 39 (16, 67) 56 (28, 80) 56 (0, 92)
MDR, multidrug-resistant; XDR, extensively drug-resistant; SD, standard deviation;
IQR, interquartile range.
Table 3
Conversion rate of patients with negative culture conversion at 4, 8, and 12 weeksa
All
drug-sensitive
Other
drug-resistant
MDR or
XDR
p-Value
Number
(total = 535)
448 52 35
4 weeks 236 (52.7) 16 (30.8) 16 (45.7) 0.010
8 weeks 342 (76.3) 33 (63.5) 21 (60.0) 0.020
12 weeks 385 (85.9) 44 (84.6) 26 (74.3) 0.176
MDR, multidrug-resistant; XDR, extensively drug-resistant.
a Values are n (%).similar. At 4 weeks, conversion rates were 47.9%, 30.8%, and 40.0%
in the DS, ODR, and MDR/XDR groups, respectively (p = 0.006). At
8 weeks, these conversion rates were 68.9%, 57.7%, and 48.6%
(p = 0.017), respectively, and at 12 weeks, they were 77.0%, 76.9%,
and 60.0% (p = 0.076), respectively.
3.3. Comparison of time to culture conversion
Among all of the 525 patients who achieved conversion, the
median time to conversion was signiﬁcantly longer in the MDR/
XDR group (median 56, IQR 0–92 days) than in the DS group
(median 39, IQR 16–67 days; p < 0.001). However, there was no
difference in the time to conversion between the MDR/XDR and
ODR groups (median 56, IQR 28–80 days; p = 0.881, Table 2). The
time to conversion was shown by Kaplan–Meier survival analysis
(Figure 1).
4. Discussion
Periodic sputum examinations are crucial for assessing
treatment responses in patients with pulmonary TB. A positive
sputum culture at 2 months of treatment is associated with an
increased risk of relapse or treatment failure.13–15 In addition,
delayed sputum culture conversion is a predictor of treatment
failure or the development of resistance.13,16 In this study, it was
found that the more drugs to which M. tuberculosis was resistant,
the slower the achievement of culture conversion, likely because of
less effective second-line anti-TB drugs. The effect of drug
resistance on conversion was most evident at 8 weeks, and was
less evident at 4 and 12 weeks of treatment.
At all three time points, the DS group showed higher conversion
rates than the other two groups. At 4 weeks of treatment, the
conversion rate was higher in the MDR/XDR group than in the ODR
group. This ﬁnding could be explained by the effects of the ﬁrst-
line anti-TB medication initially administered for patients with
MDR-TB. Some portion of MDR-TB patients are reported to achieve
conversion while on ﬁrst-line anti-TB drugs.17 The conversion rate
in the ODR group caught up with that of the MDR/XDR group at
8 weeks, and then caught up with that of the DS group at 12 weeks.
The mean time to conversion was signiﬁcantly longer in the
MDR/XDR group than in the DS or ODR groups. Although the
median values were not different in the ODR and MDR/XDR groups
P=0.003
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Figure 1. Comparison of time to culture conversion in TB patients grouped by different drug sensitivities.
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92 days) than in the ODR group (28, 80 days) resulted in a
signiﬁcant difference in time to conversion. The wide range of time
to conversion found in the MDR/XDR group could be explained by
the diverse treatment responses due to the heterogeneous
resistance patterns, as well as the modiﬁcation of anti-TB regimens
due to adverse drug events.
Previous studies have failed to determine the difference in time
to conversion between groups with different resistance.8–10 One
study compared only DS and ODR groups,8 and another compared
only ODR and MDR/XDR groups.10 Another study compared these
three groups and showed no difference in terms of time to
conversion, but only a small number of patients were included in
that study (nine patients in the MDR-TB group and 11 in the ODR-
TB group).9
The guidelines of the American Thoracic Society and Centers
for Disease Control and Prevention recommend discontinuing
respiratory precautions for patients with pulmonary TB if they
have three consecutive negative AFB sputum smear results
collected 8–24 h apart, and for patients who have received
standard anti-TB treatment (minimum of 2 weeks) and have
demonstrated a clinical improvement.18,19 The ﬁnding of slower
culture conversion in the ODR and MDR/XDR groups in the present
study suggests the necessity of longer respiratory precautions in
patients with drug-resistant TB. In addition, a wide range in time
to conversion in the ODR (IQR 28, 80) and MDR/XDR (IQR 0, 92)
groups further suggests that the duration of respiratory precau-
tions should be individualized depending on the results of sputum
studies.
This study has several limitations. First, sputum collection
times were not uniform in every patient included in this study.
Although sputum culture results at 8 weeks of treatment were
available for all of the patients included in this analysis, monthly
cultures were lacking in some patients. This may have led to an
underestimation of the conversion rates at a deﬁned time point
and an overestimation of the time to conversion. Second, the
numbers of patients included in the three groups were different,
which may have reduced the statistical power of this analysis. This
is one of the shortcomings of the study due to its retrospectivedesign. Finally, more precise classiﬁcation than that used in this
study (e.g., separation of MDR-TB and XDR-TB) could provide more
detailed information on the association between the presence of
resistance and culture conversion.
In conclusion, the pattern of resistance to anti-TB drugs affects
culture conversion rates in the early phase of treatment, as well as
the time to conversion. The effect of the drug resistance pattern on
conversion of sputum culture is most evident at 8 weeks, and less
evident at 4 and 12 weeks of treatment.
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